The customary approach to early-phase clinical trial design, where the focus is on identification of the maximum tolerated dose, is not always suitable for noncytotoxic or other targeted therapies.
Outcome-dependent sampling designs are strategic methodologies in longitudinal research that prioritise the selection of study subjects based on observed outcomes. Rather than relying on random ...